NextGen Enters Gene Synthesis Market After Licensing Gene Oracle's GeneIOS Technology | GenomeWeb
NEW YORK (GenomeWeb News) – NextGen has entered the gene-synthesis market after licensing Gene Oracle's GeneIOS gene-synthesis products and services, NextGen said today.
 
Under the agreement, NextGen will incorporate the GeneIOS technology into a new generation of ContractExpress products. The company will offer the combined technology as part of its fee-for-service offering.
 
NextGen will also offer GeneIOS as a standalone gene-synthesis product in the gene-to-protein development market.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.